Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2146962
Max Phase: Preclinical
Molecular Formula: C59H92N14O10
Molecular Weight: 1157.47
Molecule Type: Protein
Associated Items:
ID: ALA2146962
Max Phase: Preclinical
Molecular Formula: C59H92N14O10
Molecular Weight: 1157.47
Molecule Type: Protein
Associated Items:
Canonical SMILES: CC(C)[C@@H]1NC(=O)[C@H](CCCN)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CCCN)NC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CCCN)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CCCN)NC1=O
Standard InChI: InChI=1S/C59H92N14O10/c1-36(2)47-55(80)66-39(22-12-28-60)49(74)68-43(34-37-18-8-6-9-19-37)57(82)73-33-17-27-46(73)54(79)65-42(25-15-31-63)52(77)71-48(59(3,4)5)56(81)67-40(23-13-29-61)50(75)69-44(35-38-20-10-7-11-21-38)58(83)72-32-16-26-45(72)53(78)64-41(24-14-30-62)51(76)70-47/h6-11,18-21,36,39-48H,12-17,22-35,60-63H2,1-5H3,(H,64,78)(H,65,79)(H,66,80)(H,67,81)(H,68,74)(H,69,75)(H,70,76)(H,71,77)/t39-,40-,41-,42-,43+,44+,45-,46-,47-,48+/m0/s1
Standard InChI Key: MEYNQSGIZGSCTM-RDDLQERESA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1157.47 | Molecular Weight (Monoisotopic): 1156.7121 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Kapoerchan VV, Knijnenburg AD, Keizer P, Spalburg E, de Neeling AJ, Mars-Groenendijk RH, Noort D, Otero JM, Llamas-Saiz AL, van Raaij MJ, van der Marel GA, Overkleeft HS, Overhand M.. (2012) 'Inverted' analogs of the antibiotic gramicidin S with an improved biological profile., 20 (20): [PMID:22989907] [10.1016/j.bmc.2012.08.038] |
Source(1):